The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Metastatic and Locally Advanced Pancreatic Endocrine Carcinomas: Analysis of Factors Associated With Disease Progression
Abstract
Purpose: Knowledge of clinical course of pancreatic endocrine carcinomas (PECs) is poor. This study aimed to determine the time to progression of advanced PECs, and to identify predictors capable of selecting subgroups with higher risk of progression. Patients and Methods: In this multicenter retrospective analysis, patients with advanced PECs were enrolled. Staging was according to European Neuroendocrine Tumors Society guidelines. Grading was based on proliferation index using Ki67 immunohistochemistry. The primary end point was progression-free survival (PFS), which was assessed using the Kaplan-Meier method. The Cox regression proportional hazard model was used to identify predictors for tumor progression. Results: Two hundred two patients with PECs were enrolled, including 172 with well-differentiated and 30 with poorly differentiated endocrine carcinomas. There were 34 patients with stage III and 168 with stage IV tumors. G1 tumors were present in 19.7% of patients, whereas 60.1% of patients had G2 tumors, and the remaining 20.2% had G3 tumors. Disease progression occurred in 166 patients (82.2%), at a median interval of 10 months (interquartile range, 5 to 22) from diagnosis. Median PFS was 14 months. Different PFS were observed depending on G grade (P < .001) and tumor differentiation (P < .001) and in patients who did not receive any antitumor treatment (P = .002). The major risk factor for progression was the proliferation index Ki67 (hazard ratio, 1.02 for each increasing unit; P < .001). Overall 5-year survival was 44.1%. Conclusion: The vast majority of patients with advanced PECs undergo disease progression. The major risk factor for progression is Ki67 index, which should lead physicians dealing with PECs to plan appropriate follow-up programs and therapeutic strategies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
WHO Classification of Tumours of the Digestive System
Bosman, F. T. (2010) · Medical Entomology and Zoology · Cited by 5,041
Yao, J. C., Hassan, M., Phan, A., Dagohoy, C., Leary, C., Mares, J. E., Abdalla, E. K., Fleming, J. B., Vauthey, J.-N., Rashid, A., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.4377 · Cited by 4,510
Rinke, A., Müller, H.-H., Schade-Brittinger, C., Klose, K.-J., Barth, P., Wied, M., Mayer, C., Aminossadati, B., Pape, U.-F., Bläker, M., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.8510 · Cited by 2,508
TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system
Rindi, G., Klöppel, G., Alhman, H., Caplin, M., Couvelard, A., de Herder, W. W., Erikssson, B., Falchetti, A., Falconi, M., Komminoth, P., et al. (2006) · Virchows Archiv · doi:10.1007/s00428-006-0250-1 · Cited by 1,547
Self-citationGastrointestinal Neuroendocrine Tumors: Pancreatic Endocrine Tumors
Metz, D. C., & Jensen, R. T. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.05.047 · Cited by 816
The diagnosis and medical management of advanced neuroendocrine tumors.
Kaltsas, G. A., Besser, G. M., & Grossman, A. B. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0014 · Cited by 674
Kouvaraki, M. A., Ajani, J. A., Hoff, P., Wolff, R., Evans, D. B., Lozano, R., & Yao, J. C. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.04.024 · Cited by 607
Temozolomide as Monotherapy Is Effective in Treatment of Advanced Malignant Neuroendocrine Tumors
Ekeblad, S., Sundin, A., Janson, E. T., Welin, S., Granberg, D., Kindmark, H., Dunder, K., Kozlovacki, G., Örlefors, H., Sigurd, M., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2053 · Cited by 473
Scarpa, A., Mantovani, W., Capelli, P., Beghelli, S., Boninsegna, L., Bettini, R., Panzuto, F., Pederzoli, P., Fave, G. D., & Falconi, M. (2010) · Modern Pathology · doi:10.1038/modpathol.2010.58 · Cited by 422
Self-citationPanzuto, F., Nasoni, S., Falconi, M., Corleto, V. D., Capurso, G., Cassetta, S., Di Fonzo, M., Tornatore, V., Milione, M., Angeletti, S., et al. (2005) · Endocrine-Related Cancer · doi:10.1677/erc.1.01017 · Cited by 391
Self-citationPrognostic factors of long-term outcome in gastroenteropancreatic neuroendocrine tumours
Pape, U.-F., Berndt, U., Muller-Nordhorn, J., Bohmig, M., Roll, S., Koch, M., Willich, S. N., & Wiedenmann, B. (2008) · Endocrine Related Cancer · doi:10.1677/erc-08-0017 · Cited by 384
Midgut neuroendocrine tumours with liver metastases: results of the UKINETS study
Ahmed, A., Turner, G., King, B., Jones, L., Culliford, D., McCance, D., Ardill, J., Johnston, B. T., Poston, G., Rees, M., et al. (2009) · Endocrine-Related Cancer · doi:10.1677/erc-09-0042 · Cited by 274
Pelosi, G., Bresaola, E., Bogina, G., Pasini, F., Rodella, S., Castelli, P., Iacono, C., Serio, G., & Zamboni, G. (1996) · Human Pathology · doi:10.1016/s0046-8177(96)90303-2 · Cited by 267
Well-Differentiated Pancreatic Nonfunctioning Tumors/Carcinoma
Falconi, M., Plöckinger, U., Kwekkeboom, D. J., Manfredi, R., Körner, M., Kvols, L., Pape, U. F., Ricke, J., Goretzki, P. E., Wildi, S., et al. (2006) · Neuroendocrinology · doi:10.1159/000098012 · Cited by 257
Self-citationBettini, R., Boninsegna, L., Mantovani, W., Capelli, P., Bassi, C., Pederzoli, P., Delle Fave, G. F., Panzuto, F., Scarpa, A., & Falconi, M. (2008) · Annals of Oncology · doi:10.1093/annonc/mdm552 · Cited by 213
Self-citationSurvival and Prognostic Factor Analysis of 146 Metastatic Neuroendocrine Tumors of the Mid-Gut
Strosberg, J., Gardner, N. M., & Kvols, L. K. (2009) · Neuroendocrinology · doi:10.1159/000197899 · Cited by 151
Carter, D. (1987) · BMJ · doi:10.1136/bmj.294.6572.593 · Cited by 62
Endocrine Tumors of the Ileum: Factors Correlated with Survival
Tomassetti, P., Campana, D., Piscitelli, L., Casadei, R., Nori, F., Brocchi, E., Santini, D., Pezzilli, R., & Corinaldesi, R. (2006) · Neuroendocrinology · doi:10.1159/000096053 · Cited by 42
Self-citation
Cited by
Falconi, M., Eriksson, B., Kaltsas, G., Bartsch, D. K., Capdevila, J., Caplin, M., Kos-Kudla, B., Kwekkeboom, D., Rindi, G., Klöppel, G., et al. (2016) · Neuroendocrinology · doi:10.1159/000443171 · Cited by 1,362
Self-citationNeuroendocrine and Adrenal Tumors, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
Shah, M. H., Goldner, W. S., Benson, A. B., Bergsland, E., Blaszkowsky, L. S., Brock, P., Chan, J., Das, S., Dickson, P. V., Fanta, P., et al. (2021) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2021.0032 · Cited by 619
Falconi, M., Bartsch, D. K., Eriksson, B., Klöppel, G., Lopes, J. M., O'Connor, J. M., Salazar, R., Taal, B. G., Vullierme, M. P., & O'Toole, D. (2012) · Neuroendocrinology · doi:10.1159/000335587 · Cited by 526
Self-citationGastroenteropancreatic high‐grade neuroendocrine carcinoma
Sorbye, H., Strosberg, J., Baudin, E., Klimstra, D. S., & Yao, J. C. (2014) · Cancer · doi:10.1002/cncr.28721 · Cited by 347
Are G3 ENETS neuroendocrine neoplasms heterogeneous?
Vélayoudom-Céphise, F.-L., Duvillard, P., Foucan, L., Hadoux, J., Chougnet, C. N., Leboulleux, S., Malka, D., Guigay, J., Goere, D., Debaere, T., et al. (2013) · Endocrine-Related Cancer · doi:10.1530/erc-13-0027 · Cited by 325
Metadata
- Authors
- Panzuto, F., Boninsegna, L., Fazio, N., Campana, D., Pia Brizzi, M., Capurso, G., Scarpa, A., De Braud, F., Dogliotti, L., Tomassetti, P., Delle Fave, G., & Falconi, M.
- Venue
- Journal of Clinical Oncology
- Published
- 2011-06-10
- Volume
- 29
- Issue
- 17
- Pages
- 2372-2377
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2140794446
- Cited by
- 285
- References
- 18
- FWCI
- 12.53
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.